Bone Mineral Density Assessment — MCQs
Treatment of post menopausal osteoporosis are all EXCEPT
A 70-year-old female has been on alendronate for 7 years for osteoporosis and now complains of pain in her right thigh. What is the next investigation to be performed?
A female is on hormone replacement therapy for her menopausal symptoms. She is worried about her bone strength because her mom and sister had osteoporosis after the age of 50. All are given for prevention of osteoporosis along with hormonal replacement therapy, EXCEPT:
Osteoporosis is seen in all the following except
Which clinical sign is consistently present in all bone fractures?
Drug of choice for post menopausal osteoporosis is
Which of the following is the first-line management for postmenopausal women with osteoporosis?
In Osteoporosis which of these is seen?
Brittle bone disease is -
Which of the following is an osteoporotic fracture?
Bone Mineral Density Assessment Indian Medical PG Practice Questions and MCQs
Question 1: Treatment of post menopausal osteoporosis are all EXCEPT
- A. Estrogen
- B. Magnesium and Zinc (Correct Answer)
- C. Calcium, Vit D supplementation
- D. Raloxifene
Explanation: ***Magnesium and Zinc*** - While **magnesium** and **zinc** are essential for overall health, their role as primary therapeutic agents for established postmenopausal osteoporosis is **unproven** and is not standard treatment. - They are considered **trace elements** and their deficiency can affect bone health, but supplementation alone is not sufficient to treat osteoporosis. *Estrogen* - **Estrogen replacement therapy** was historically used for postmenopausal osteoporosis due to its role in preventing bone loss, but its use is now limited due to **adverse effects** like increased risk of breast cancer and cardiovascular events [1]. - It is still considered in select cases for symptom relief and bone health, but generally at the lowest effective dose for the shortest duration [1]. *Calcium, Vit D supplementation* - **Calcium and Vitamin D supplementation** are fundamental components of osteoporosis management by supporting bone mineralization and calcium homeostasis [2]. - Adequate intake is critical for both **prevention** and **treatment**, often used in conjunction with other pharmacologic agents [2]. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that acts as an estrogen agonist on bone, thereby reducing bone resorption and increasing bone mineral density [1]. - It is used in the treatment and prevention of postmenopausal osteoporosis, with the added benefit of reducing the risk of invasive breast cancer [1].
Question 2: A 70-year-old female has been on alendronate for 7 years for osteoporosis and now complains of pain in her right thigh. What is the next investigation to be performed?
- A. DEXA scan
- B. Serum vitamin D levels
- C. Serum alkaline phosphate levels
- D. X-ray (Correct Answer)
Explanation: **X-ray** - Alendronate, a **bisphosphonate**, is associated with **atypical femoral fractures** after prolonged use, and an X-ray is the most appropriate initial investigation to visualize such a fracture. - Complaints of thigh pain in a patient on long-term bisphosphonate therapy should prompt imaging to rule out this serious complication. *DEXA scan* - A DEXA scan assesses **bone mineral density** but does not provide information about acute fractures or structural integrity in response to specific pain. - While it's used for osteoporosis diagnosis and monitoring, it won't directly identify an atypical femoral fracture. *Serum vitamin D levels* - Maintaining adequate **vitamin D levels** is important for bone health, but its measurement won't explain acute thigh pain or identify a fracture. - Low vitamin D levels can contribute to osteoporosis but are not the primary cause of pain suggestive of an atypical femoral fracture. *Serum alkaline phosphate levels* - **Alkaline phosphatase** levels can be elevated in conditions involving increased bone turnover, such as healing fractures or certain bone diseases. - However, it is not a direct diagnostic tool for identifying atypical femoral fractures and would not be the first line investigation.
Question 3: A female is on hormone replacement therapy for her menopausal symptoms. She is worried about her bone strength because her mom and sister had osteoporosis after the age of 50. All are given for prevention of osteoporosis along with hormonal replacement therapy, EXCEPT:
- A. Calcium
- B. Vitamin-E (Correct Answer)
- C. Vit.D
- D. None of the options
Explanation: ***Vitamin-E*** - **Vitamin-E** is an **antioxidant** vitamin that primarily protects cells from oxidative damage. - It does not play a direct role in **bone metabolism** or the prevention of osteoporosis. *Calcium* - **Calcium** is a fundamental component of bone tissue and is essential for maintaining **bone density** [1]. - Adequate calcium intake is crucial for **osteoporosis prevention**, especially in postmenopausal women [1], [2]. *Vit.D* - **Vitamin D** is essential for **calcium absorption** in the gut and its incorporation into bones. - Without sufficient Vitamin D, calcium cannot be effectively utilized, leading to compromised **bone health**. *None of the options* - This option is incorrect because Vitamin E does not contribute to osteoporosis prevention, making it the correct answer to the "EXCEPT" question. - Calcium and Vitamin D are both vital for bone strength, so stating that none of the options fit would be inaccurate [1].
Question 4: Osteoporosis is seen in all the following except
- A. Steroid therapy
- B. Rheumatoid arthritis
- C. Thyrotoxicosis
- D. Hypoparathyroidism (Correct Answer)
Explanation: ***Hypoparathyroidism*** - Hypoparathyroidism leads to low levels of **parathyroid hormone (PTH)**, which causes **hypocalcemia** and **hyperphosphatemia**. - This condition is associated with **increased bone density** and sometimes osteosclerosis, rather than osteoporosis. *Steroid therapy* - **Glucocorticoids** inhibit osteoblast function and promote osteoclast activity, leading to **bone demineralization** and osteoporosis [1]. - This is a common cause of secondary osteoporosis, especially with long-term systemic use [1]. *Rheumatoid arthritis* - **Chronic inflammation** in rheumatoid arthritis contributes to generalized bone loss and osteoporosis [1]. - Additionally, patients often receive **glucocorticoid treatment**, which further exacerbates bone loss [1]. *Thyrotoxicosis* - **Excessive thyroid hormone** directly stimulates bone remodeling, increasing both bone formation and resorption. - However, the increase in **resorption outpaces formation**, leading to overall bone loss and a higher risk of osteoporosis.
Question 5: Which clinical sign is consistently present in all bone fractures?
- A. Tenderness
- B. None of the options (Correct Answer)
- C. Crepitus
- D. Abnormal mobility
Explanation: ***None of the options*** - No single clinical sign is **consistently present** in all bone fractures, as presentations vary depending on the bone, fracture type, and patient factors. - While many signs are common, some fractures can be **subtle or atypical**, making a single universal sign an impossibility. *Crepitus* - **Crepitus** (a grating or crackling sound/sensation) occurs when fractured bone ends rub against each other. - It is not always present, especially in **impacted fractures** or when displacement is minimal, and often indicates significant instability. *Tenderness* - While localized **tenderness** is a very common sign of fracture, it is not universally present in all cases. - For example, in **stress fractures** or some pathological fractures, pain may be diffuse or less acutely localized. *Abnormal mobility* - **Abnormal mobility** at a site not normally a joint is a strong indication of a complete fracture and significant displacement. - However, it is absent in **incomplete fractures** (e.g., greenstick, hairline), impacted fractures, or when the fracture is well-stabilized.
Question 6: Drug of choice for post menopausal osteoporosis is
- A. Bisphosphonates (Correct Answer)
- B. Estrogen
- C. Thyroxine
- D. Teriparatide
Explanation: ***Bisphosphonates*** - **Bisphosphonates** are considered the **first-line therapy** for established postmenopausal osteoporosis due to their proven efficacy in reducing the risk of vertebral and non-vertebral fractures. - They work by **inhibiting osteoclast activity**, thereby decreasing bone resorption and increasing bone mineral density. *Estrogen* - While **estrogen therapy** can prevent osteoporosis, it is generally not the first-line treatment due to potential risks like increased risk of **breast cancer**, **stroke**, and **venous thromboembolism**. - It is typically reserved for women with severe menopausal symptoms who also require osteoporosis prevention, and often used at the **lowest effective dose for the shortest duration**. *Thyroxine* - **Thyroxine** is a hormone used primarily to treat **hypothyroidism**, a condition where the thyroid gland doesn't produce enough thyroid hormone. - It is **not indicated for the treatment of osteoporosis** and can even worsen bone loss if given in excessive doses, leading to iatrogenic hyperthyroidism. *Teriparatide* - **Teriparatide** is an **anabolic agent** that stimulates new bone formation, making it a powerful option for severe osteoporosis or those who have failed other therapies. - However, it is an injectable medication with a **limited treatment duration** (typically 2 years) and is generally reserved for patients with a **high fracture risk** rather than being the initial drug of choice for all postmenopausal osteoporosis.
Question 7: Which of the following is the first-line management for postmenopausal women with osteoporosis?
- A. Calcitonin
- B. Raloxifene
- C. Tamoxifen
- D. Bisphosphonates (Correct Answer)
Explanation: ***Bisphosphonates*** - **Bisphosphonates** are the **first-line therapy** for postmenopausal osteoporosis due to their proven efficacy in reducing the risk of fragility fractures. - They work by **inhibiting osteoclast activity**, thereby decreasing bone resorption and increasing bone mineral density. *Calcitonin* - **Calcitonin** is a hormone that inhibits bone resorption, but its **anti-fracture efficacy is weaker** than bisphosphonates. - It is typically used as a **second-line agent** or for patients who cannot tolerate bisphosphonates, often for its analgesic effect in vertebral compression fractures. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that mimics estrogen's beneficial effects on bone. - While it helps prevent vertebral fractures, it is **less effective than bisphosphonates** at preventing non-vertebral fractures and carries a risk of venous thromboembolism. *Tamoxifen* - **Tamoxifen** is also a **SERM**, primarily used in the treatment of **estrogen receptor-positive breast cancer**. - While it has **estrogen-like effects on bone** and can improve bone density, it is not approved or routinely used for the primary management of osteoporosis due to its other systemic effects and risks.
Question 8: In Osteoporosis which of these is seen?
- A. Normal calcium, decreased ALP
- B. Decreased calcium, increased ALP
- C. Normal calcium, normal ALP (Correct Answer)
- D. Decreased calcium, decreased ALP
Explanation: ***Normal calcium, normal ALP*** - In **osteoporosis**, the primary defect is a reduction in **bone mass** due to imbalanced bone remodeling, but the remaining bone tissue is normally mineralized [1]. - Therefore, **serum calcium** and **alkaline phosphatase (ALP)**, which reflect bone turnover and mineralization, typically remain within normal ranges [3]. *Normal calcium, decreased ALP* - While **serum calcium** is usually normal in osteoporosis, **decreased ALP** is not a characteristic finding. - Decreased ALP might indicate conditions like **hypophosphatasia** or certain nutritional deficiencies, which are distinct from osteoporosis. *Decreased calcium, increased ALP* - **Decreased serum calcium** (hypocalcemia) combined with **increased ALP** is often seen in conditions like **osteomalacia** or **rickets**, where there is defective bone mineralization [2]. - This pattern is not typical of osteoporosis, where the problem is a quantitative reduction in bone, not qualitative mineralization defect [3]. *Decreased calcium, decreased ALP* - A combination of **decreased calcium** and **decreased ALP** is an unusual biochemical profile in bone disorders. - It could potentially be seen in severe malnutrition leading to multiple deficiencies, but it is not indicative of osteoporosis.
Question 9: Brittle bone disease is -
- A. Osteoporosis
- B. Pagets disease
- C. Osteopetrosis
- D. Osteogenesis imperfecta (Correct Answer)
Explanation: ***Osteogenesis imperfecta*** - **Osteogenesis imperfecta** is an inherited disorder characterized by **brittle bones** that fracture easily, due to a defect in **collagen type I** synthesis. - Patients often present with **blue sclera**, **dentinogenesis imperfecta**, and **hearing loss**, in addition to frequent fractures. *Osteoporosis* - **Osteoporosis** is a condition of **decreased bone density**, making bones fragile and prone to fracture, but it is not typically referred to as "brittle bone disease" in the same congenital sense. - It is more common in older adults and is often related to **hormonal changes** (e.g., post-menopause) or lifestyle factors. *Paget's disease* - **Paget's disease of bone** involves abnormal bone remodeling with excessive bone resorption followed by disorganized and expanded bone formation, leading to **enlarged, weakened bones**. - It typically affects older individuals and can lead to bone pain, deformities, and fractures, but it's not the primary condition associated with "brittle bone disease." *Osteopetrosis* - **Osteopetrosis** is characterized by **abnormally dense bones** due to impaired osteoclast function, leading to a buildup of bone. - While bones are dense, they are also **brittle** and prone to fracture, and the condition is also known as "marble bone disease" rather than "brittle bone disease."
Question 10: Which of the following is an osteoporotic fracture?
- A. Vertebrae (Correct Answer)
- B. Midshaft of Humerus
- C. Glenoid Fracture
- D. Subtrochanteric Fracture
Explanation: ***Vertebrae*** - **Vertebral compression fractures** are among the most common osteoporotic fractures, often occurring spontaneously or due to minimal trauma. - They are significant because they can lead to **loss of height**, **kyphosis**, and chronic back pain. *Midshaft of Humerus* - Fractures of the **midshaft of the humerus** are generally associated with direct trauma or high-energy impacts, rather than fragility due to osteoporosis. - While possible in osteoporotic individuals, they are not considered a classic or common osteoporotic fracture site compared to others. *Glenoid Fracture* - A **glenoid fracture** typically results from a **high-energy impact** to the shoulder, such as a fall directly onto the shoulder or a dislocation. - It is not typically classified as a common osteoporotic fracture, which are usually fragility fractures from low-energy trauma. *Subtrochanteric Fracture* - **Subtrochanteric femoral fractures** are located just below the lesser trochanter. While the femur is a common site for osteoporotic fractures (e.g., femoral neck), subtrochanteric fractures are often associated with falls from a greater height or high-impact trauma. - Historically, they have also been linked to long-term use of certain anti-resorptive medications like **bisphosphonates**, which can paradoxically increase the risk of these atypical femur fractures with prolonged use.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free